Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Clene Inc

Healthcare US CLNNW

NoneUSD
0.00(0%)

Last update at 2026-01-29T21:04:19.767268Z

Day Range

--
LowHigh

52 Week Range

0.020.12
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap646.98M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-37.31700M
  • Revenue TTM0.62M
  • Revenue Per Share TTM0.005
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -49.50400M -29.91800M -10.16800M -18.87100M -16.15500M
Minority interest - - - - -
Net income -49.50400M -15.27900M -9.74000M -19.27700M -16.27000M
Selling general administrative 13.10M 16.94M 18.81M 5.15M 6.77M
Selling and marketing expenses 1.05M - - - -
Gross profit -1.17200M 0.45M 0.43M 0.14M -0.90000M
Reconciled depreciation 1.59M 1.02M 0.95M 0.96M 0.85M
Ebit -40.54000M -45.33000M -45.27600M -17.00400M -16.33200M
Ebitda -38.83500M -45.07300M -47.51600M -16.00700M -14.85800M
Depreciation and amortization 1.71M 0.26M -2.24000M 1.00M 1.47M
Non operating income net other - 21.79M 40.68M 2.29M -
Operating income -40.54000M -45.33000M -45.27600M -17.00400M -16.33200M
Other operating expenses 41.19M 45.80M 46.00M 17.21M 15.73M
Interest expense 4.56M 3.30M 0.87M 0.95M 0.09M
Tax provision 0.00000M -0.21500M -0.42800M 0.41M 0.00000M
Interest income 1.39M 0.23M - 13.20M -
Net interest income -4.55600M -4.06900M -4.05300M -0.95000M -0.08800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -14.63900M -0.42800M 0.41M 0.12M
Total revenue 0.65M 0.47M 0.72M 0.21M 0.00000M
Total operating expenses 39.37M 45.78M 45.71M 17.14M 15.73M
Cost of revenue 1.83M 0.03M 0.29M 0.07M 0.90M
Total other income expense net -8.96400M 15.41M 35.11M -1.86700M 0.18M
Discontinued operations - - - - -
Net income from continuing ops -40.38500M -29.91800M -9.74000M -19.27700M -16.15500M
Net income applicable to common shares - -29.91800M -9.74000M -19.27700M -
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 52.34M 44.49M 63.06M 68.24M 14.88M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 2.48M 5.65M 0.17M 0.11M 0.06M
Total liab 38.95M 41.26M 50.47M 67.90M 82.65M
Total stockholder equity 13.39M 3.24M 12.60M 0.34M -67.77400M
Deferred long term liab - - 18.10M 0.26M -
Other current liab 3.72M 3.86M 3.61M 10.05M 3.01M
Common stock 0.01M 0.00700M 0.00600M 0.00600M 0.00200M
Capital stock 0.01M 0.00700M 0.00600M 0.00600M 0.00200M
Retained earnings -242.72300M -193.21900M -163.30100M -153.56100M -69.57100M
Other liab - - - - -
Good will - - - - -
Other assets - - - 1.03M 48.30M
Cash 28.82M 18.33M 50.29M 59.27M 8.79M
Cash and equivalents - - - - -
Total current liabilities 25.33M 13.86M 6.03M 11.67M 4.31M
Current deferred revenue 0.00000M - - 0.11M -
Net debt 3.34M 13.49M -26.24600M -54.95200M -5.90900M
Short term debt 20.11M 6.98M 0.49M 0.38M 0.42M
Short long term debt 19.50M 6.42M - - -
Short long term debt total 32.16M 31.82M 24.04M 4.32M 2.88M
Other stockholder equity 255.90M 196.25M 175.66M 85.33M 1.75M
Property plant equipment - - 5.17M 5.25M -
Total current assets 38.85M 29.20M 54.58M 62.99M 9.48M
Long term investments - - - - -
Net tangible assets - 3.24M 12.60M 0.34M -
Short term investments 6.18M 4.98M - - -
Net receivables 1.34M 0.19M 1.61M 2.17M 0.60M
Long term debt 7.15M 19.25M 14.48M 1.95M 0.64M
Inventory 0.04M 0.04M 0.04M 0.19M 0.03M
Accounts payable 1.50M 3.01M 1.92M 1.12M 0.89M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.20M 0.20M 0.23M 0.33M 0.04M
Additional paid in capital - - - - -
Common stock total equity - 0.00700M 0.00600M 0.00600M 0.00200M
Preferred stock total equity - - - - -
Retained earnings total equity - -193.21900M -163.30100M -153.56100M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.06M 0.06M 0.06M -0.26000M -
Deferred long term asset charges - - - - -
Non current assets total 13.49M 15.30M 8.48M 5.25M 5.40M
Capital lease obligations 5.51M 6.15M 4.96M 2.37M 2.24M
Long term debt total - - 14.48M 1.95M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -4.98500M -1.33200M -0.38700M -0.29400M -
Change to liabilities 0.54M 2.33M -0.30800M - -
Total cashflows from investing activities -10.16400M -1.33200M -0.38700M - -46.00000M
Net borrowings 5.61M 19.46M 6.78M - -
Total cash from financing activities 17.25M 27.11M 69.53M 5.50M 46.95M
Change to operating activities - - - - -
Net income -29.91800M -9.74000M -19.27700M -16.15500M 0.02M
Change in cash -31.95600M -8.92900M 50.49M -7.98900M 0.74M
Begin period cash flow 50.35M 59.27M 8.79M 16.78M -
End period cash flow 18.39M 50.35M 59.27M 8.79M 16.78M
Total cash from operating activities -39.01100M -34.62400M -18.92900M -13.19700M -0.20537M
Issuance of capital stock 11.46M 9.25M 35.05M 8.07M -
Depreciation 1.02M 0.95M 0.96M 0.85M -
Other cashflows from investing activities - - - - -46.00000M
Dividends paid - - - - -
Change to inventory -0.00200M 0.15M -0.16300M -0.02800M -
Change to account receivables -0.14000M -0.02800M -3.24300M - -
Sale purchase of stock 11.77M 7.80M 66.96M - 48.17M
Other cashflows from financing activities 5.92M 18.02M 34.68M 8.68M -1.22585M
Change to netincome 8.35M 10.66M 16.25M - -
Capital expenditures 5.18M 1.33M 0.39M 0.29M 0.00000M
Change receivables -0.14000M -0.02800M - - -
Cash flows other operating -19.71700M -38.95800M -16.57800M - -
Exchange rate changes - -0.08500M 0.27M - -
Cash and cash equivalents changes -31.92600M -8.92900M 50.49M - -
Change in working capital -1.54000M 1.00M -3.34600M 1.16M 0.12M
Stock based compensation 8.51M 12.38M 0.76M 0.40M -
Other non cash items -17.08500M -37.59500M -13.15600M 0.19M -
Free cash flow -44.19000M -35.95600M -19.31600M -13.49100M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
CLNNW
Clene Inc		 - -% - - - - -
NVO
Novo Nordisk A/S		 0.03 0.05% 47.45 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.16 2.48% 48.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 8.43 1.80% 476.85 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 7.92 1.28% 625.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Clene Inc

6550 South Millrock Drive, Salt Lake City, UT, United States, 84121

Key Executives

Name Title Year Born
Mr. Rob Etherington CEO, Pres & Director NA
Mr. Mark G. Mortenson Co-Founder & Chief Scientific Officer 1958
Dr. Robert Glanzman M.D. Chief Medical Officer 1957
Dr. Jeong Ted Chief Financial Officer NA
Mr. Jerry Miraglia J.D. Gen. Counsel & Corp. Sec. NA
Mr. Michael Hotchkin Chief Devel. Officer NA
Ms. Mary Anne Mcneil Head of HR NA
Mr. Robert Etherington MBA CEO, President & Director 1967
Mr. Morgan R. Brown CPA, M.B.A. Chief Financial Officer 1968
Mr. Mark G. Mortenson ESQ. Chief Science Officer 1958

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.